AstraZeneca and Daiichi Sankyo have chalked up another positive trial for their HER2-directed antibody-drug conjugate Enhertu in early breast cancer, this time in the 'post-neoadjuvant' setting. The ...
AstraZeneca and Daiichi Sankyo pushed back the readout of their trial of Datroway in triple-negative breast cancer (TNBC) patients ineligible for frontline immunotherapies, but the result has been ...
Registration Questions? **Please note we have pricing tiers based on ticket availability. Ticket prices will increase once we sell out of the current pricing tier. We cannot redeem a lower price once ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback